Clinical trial of gefitinib for advanced lung cancer closes early Researchers have closed a randomized clinical trial comparing gefitinib vs caverta 100mg . Placebo following chemotherapy and radiation for patients with non-little cell lung malignancy that got spread and then nearby cells or lymph nodes. Review of interim data indicated that gefitinib would not improve survival. The medical trial was sponsored by the National Cancer tumor Institute , and was conducted by a network of experts led by the Southwest Oncology Group , Ann Arbor, Mich.
Spellberg, M.D. ‘These data are encouraging for the millions of men diagnosed with prostate cancer searching for a noninvasive therapy which will preserve their quality of life.’ ‘I was searching for a treatment that offered the best opportunity for a complete treatment, but at the same time, it was vitally important to me in order to avoid the problems – impotence, incontinence and bowel problems – that commonly derive from prostate cancer treatment,’ said study participant and retired Orthopedic Surgeon Scott Silver, M.D. ‘I am very happy to report three. 5 years post-treatment, I stay cancer-free with my standard of living 100 % intact.’..